KLOW

What is KLOW?

Tissue recovery involves overlapping processes: inflammation resolution, matrix remodeling, angiogenesis, cell migration, and antimicrobial defense. KLOW combines four peptides with complementary mechanisms to address these phases simultaneously. Each component targets distinct pathways: GHK-Cu modulates over 4,000 genes involved in tissue remodeling and collagen synthesis, BPC-157 promotes cytoprotection and angiogenesis, TB-500 drives cell migration through actin regulation, and KPV provides anti-inflammatory signaling through MSH receptor pathways.

Where individual peptides excel at specific repair phases, KLOW's multi-peptide approach models comprehensive tissue regeneration. The formulation recognizes that recovery bottlenecks rarely exist in isolation—addressing inflammation without supporting matrix synthesis, or promoting cell migration without adequate vascular supply, limits overall healing capacity. By combining these mechanisms in a single preparation, KLOW serves as a research tool for investigating synergistic tissue repair pathways.

Component Mechanisms

GHK-Cu (50mg) — Matrix Remodeling & Gene Regulation

GHK-Cu (Gly-His-Lys copper complex) functions as a pleiotropic signaling molecule, modulating expression of genes involved in extracellular matrix synthesis, metalloproteinase activity, and growth factor production. Studies demonstrate GHK-Cu upregulates decorin, p63, and multiple collagens while suppressing TGF-β1 and matrix metalloproteinases associated with excessive scarring. The copper moiety enhances superoxide dismutase (SOD) activity, providing antioxidant protection during inflammatory phases of tissue repair.

BPC-157 (10mg) — Cytoprotection & Angiogenesis

BPC-157 demonstrates cytoprotective properties through stabilization of cellular membranes and modulation of nitric oxide pathways. The peptide enhances VEGF expression and activates the FAK-paxillin pathway in endothelial cells, promoting angiogenesis critical for vascular supply to healing tissue. Additionally, BPC-157 stabilizes gastric pentadecapeptide structures and promotes expression of heat shock proteins that protect cells under metabolic stress.

TB-500 (10mg) — Cell Migration & Actin Dynamics

TB-500 (Thymosin Beta-4 fragment) regulates actin polymerization, facilitating cell migration into injury sites. As a G-actin sequestering peptide, TB-500 modulates cytoskeletal dynamics essential for endothelial cell and keratinocyte movement. The peptide upregulates matrix metalloproteinases (MMP-2, MMP-9) to enable extracellular matrix remodeling and promotes differentiation of endothelial progenitor cells supporting new vessel formation.

KPV (10mg) — Inflammation Modulation

KPV (Lys-Pro-Val) represents the C-terminal tripeptide of α-MSH, retaining anti-inflammatory activity through melanocortin receptor signaling. The peptide suppresses NF-κB translocation and reduces pro-inflammatory cytokine expression (TNF-α, IL-1β, IL-6) in activated immune cells. Unlike full-length α-MSH, KPV demonstrates activity without melanogenic effects, making it suitable for tissue repair models where inflammation modulation is required without pigmentation confounds.

Synergistic Rationale

The KLOW formulation addresses tissue repair as a multi-phase process:

• Phase 1 (Inflammatory Control): KPV modulates inflammatory signaling to prevent excessive tissue damage
• Phase 2 (Cytoprotection & Vascular Supply): BPC-157 protects existing cells and promotes angiogenesis to support metabolic demands
• Phase 3 (Cell Migration): TB-500 facilitates movement of repair cells into injury sites through actin regulation
• Phase 4 (Matrix Synthesis & Remodeling): GHK-Cu drives collagen production and matrix organization for structural restoration

By combining these mechanisms, KLOW models the coordinated signaling required for complete tissue regeneration—from initial injury response through final structural remodeling.

Key Research Findings

• GHK-Cu modulates expression of over 4,000 genes involved in tissue remodeling, with 47% upregulation of decorin and 70% suppression of TGF-β1 in fibroblast cultures (Pickart & Margolina, 2018)
• BPC-157 accelerates tendon healing by 72% in rat Achilles transection models through enhanced VEGF expression and collagen organization (Chang et al., 2011)
• TB-500 increases endothelial cell migration by 250% through upregulation of integrin-linked kinase (ILK) pathway and MMP-2/9 activity (Goldstein et al., 2012)
• KPV reduces pro-inflammatory cytokine expression (TNF-α, IL-1β, IL-6) by 60-80% in LPS-activated macrophages without melanogenic effects (Brzoska et al., 2008)
• Multi-peptide combinations demonstrate synergistic effects on wound closure rates exceeding individual peptides by 35-40% in dermal injury models (Tarnawski et al., 2016)

Research Applications

• Multi-pathway wound healing models (acute and chronic)
• Tissue regeneration and repair mechanism studies
• Inflammation-to-repair transition research
• Angiogenesis and neovascularization assays
• Cell migration and chemotaxis investigations
• Extracellular matrix remodeling and collagen synthesis studies
• Comparative single-peptide vs multi-peptide synergy research
• Musculoskeletal tissue repair models (tendon, ligament, muscle)
• Dermal wound closure and scar formation studies
• Anti-inflammatory pathway modulation without immunosuppression

Reconstitution

Reconstitute with bacteriostatic water to desired concentration. All four components remain stable when co-reconstituted and do not interact. Use our peptide calculator to determine optimal reconstitution volume based on target concentration.

Storage & Handling

Store lyophilized powder at -20°C protected from light and moisture. After reconstitution, maintain at 2-8°C and use within 30 days. The four-peptide combination remains stable under standard refrigerated storage conditions.